+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Acute Lymphoblastic Leukemia Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4833392
  • Report
  • September 2019
  • Region: Global
  • 115 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Celegene Corporation
  • Eisai Co Ltd
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GlaxoSmithKline
  • MORE
Market Overview

One of the major factors responsible for the growth of this market includes the rising occurrence of Acute Lymphoblastic Leukemia (ALL) globally. The number of new cases being recorded each year is around 1.7 per 100,000 men & women per year. It has been estimated by the American Cancer Institute that in the year 2019, there will be around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females. In addition, by 2020, it has been estimated that the number of cases of ALL should range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries.

There is a rise in the number of cases in the Asia-Pacific region primarily due to the adoption of western lifestyles including dietary changes and sedentary lifestyles. Also, globally, the prevalence is expected to increase in the forecast period, which shall be the major factor for the growth of this market.

Other factors that should be taken into account are rising preference towards targeted therapy use in cancer treatment, the rise in the number of bone marrow biopsies, and increasing overall investments in research and development.

Scope of the Report

Acute lymphoblastic leukemia (ALL), also called as lymphoblastic leukemia, is one of the most common types of cancer during childhood which spreads in the body through lymph nodes, spinal cord, liver, spleen, central nervous system, amongst others. B-cell ALL, T-cell ALL, and Philadelphia chromosome-positive ALL (Ph+ ALL) are three of the most common primary types of ALL. B-cell ALL is the most common type. The treatment of patients with Ph+ ALL involves precise drugs which target the gene products.

Key Market Trends

Chemotherapy to Dominate the Type of Therapy Segment

American Cancer Association has stated that chemotherapy is the main treatment for the people suffering from Acute Lymphoblastic Leukemia (ALL) and it is given in three phases such as Remission, Consolidation, and Maintenance. Chemotherapy uses cytotoxic drugs for the destruction of the cancer cells.

Amsacrine (NordMedica), Cyclophosphamide (Baxter), cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in ALL. Global pharmaceutical players such as Baxter International, Pfizer, are providing these drugs.

It has been stated by the association named Indian Pediatrics that, chemotherapy is helping in the reduction of mortality rate due to ALL and acting as the most trusted treatment option available. Therefore, the rising importance of chemotherapy is contributing to the higher growth of this segment.

North America to Dominate the Market

North America is expected to dominate this market due to the rising number of cases of this disease in the region owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market. Asia-Pacific is also expected to grow at a high CAGR during the forecast period owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.

Competitive Landscape

The market for Acute Lymphoblastic Leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on Oncology, it is expected that few new small-sized companies will also penetrate the market in the near future.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Celegene Corporation
  • Eisai Co Ltd
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GlaxoSmithKline
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia
4.2.2 Increasing Preference to Shift Towards the Targeted Therapy Use
4.2.3 Increasing Initiatives Taken by the Government and Private Organizations
4.3 Market Restraints
4.3.1 Stringent Regulatory Pathways
4.3.2 High Cost Asscoiated with the Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Cell
5.1.1 B-cell ALL
5.1.2 T-cell ALL
5.1.3 Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL
5.2 By Type of Therapy
5.2.1 Chemotherapy Hyper - CVAD Regimen CALGB 8811 Regimen Linker Regimen Nucleoside Inhibitors Others
5.2.2 Targeted Therapy
5.2.3 Radiation Therapy
5.2.4 Stem Cell Transplantation
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Bristol Myer Squibb Company
6.1.2 Celegene Corporation
6.1.3 Eisai Co Ltd
6.1.4 Erytech Pharma
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Genmab A/S
6.1.7 GlaxoSmithKline
6.1.8 Novartis AG
6.1.9 Pfizer Inc
6.1.10 Sanofi SA
6.1.11 SymBio Pharmaceuticals Limited

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Bristol Myer Squibb Company
  • Celegene Corporation
  • Eisai Co Ltd
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GlaxoSmithKline
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • SymBio Pharmaceuticals Limited
Note: Product cover images may vary from those shown